Fei Yin

机构：Hebei Medical University, Liaocheng University, Tohoku University, Lanzhou University of Technology, Fourth Hospital of Hebei Medical University, Second Affiliated Hospital of Jilin University · ORCID：0000-0003-2430-9267

发表论文 45 篇 · 总被引 475 次 · h-index 14

代表论文

• High-throughput fluorescence lifetime imaging flow cytometry (2024 · Nature Communications · 被引 35)
• Prognosis of hepatocellular carcinoma and its association with immune cells using systemic inflammatory response index (2022 · Future Oncology · 被引 30)
• Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trial (2024 · European Journal of Cancer · 被引 21)
• Correlation between immune‑related adverse events and treatment efficacy of anti‑PD1 immunotherapy in patients with esophageal squamous cell carcinoma (2022 · Oncology Letters · 被引 16)
• Immune cell senescence in autoimmunity: implications for disease pathogenesis and therapeutic targeting (2025 · Frontiers in Immunology · 被引 14)
• Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib (2023 · Technology in Cancer Research & Treatment · 被引 14)